Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Investor Alert: Faruqi & Faruqi LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

New York, NY – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating claims against Pliant Therapeutics, Inc. ("Pliant Therapeutics" or the "Company") (NASDAQ: PLNT) on behalf of its investors.

The investigation centers on whether Pliant Therapeutics has made any false or misleading statements to the public or its investors. The investigation is also focusing on whether the Company has failed to disclose material information, including the potential impact of its recent clinical trial results on its business, financial condition, and prospects.

Pliant Therapeutics is a biotechnology company focused on developing novel therapeutics for the treatment of various diseases. On March 16, 2023, the Company announced that it would be discontinuing its Phase 2 clinical trial for PLN-101, one of its lead product candidates. The Company cited a lack of efficacy as the reason for the discontinuation.

Faruqi & Faruqi, LLP is seeking information from investors who may have suffered losses as a result of Pliant Therapeutics' alleged wrongdoing. If you have any information or would like to learn more about the investigation, please contact Faruqi & Faruqi, LLP's James Bruce at (877) 247-4282 or jbruce@faruqilaw.com.

Faruqi & Faruqi, LLP is a national securities law firm with decades of experience in securities litigation and arbitration. The firm has litigated numerous cases on behalf of investors and employees who have been harmed by corporate wrongdoing. The firm's attorneys have extensive experience in investigating and prosecuting claims against publicly traded companies and their executives, including claims related to securities fraud, corporate governance, and shareholder rights.